

December 13, 2022

---

# **Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer**

San Diego, California--(Newsfile Corp. - December 13, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives, has hired Chris Twitty, PhD, as the Company's first chief scientific officer (CSO). With over 25 years of life science research and drug development experience, he will be a key member of Skye's executive team with responsibility for leading the strategic development of Skye's scientific estate.

Dr. Twitty has led R&D and translational efforts to expand drug pipelines and supported multiple IND filings for novel therapeutics. He has additionally contributed to CMC, non-clinical, regulatory and clinical development efforts necessary to initiate clinical trials. He has significant experience in biomarker discovery and clinical biomarker strategies.

Dr. Twitty was most recently CSO at Onchilles Pharma. Prior to that he was Director and Head of Clinical Sciences and then VP of R&D and CSO at Oncosec Medical. He began his career at Bayer and also worked in research at Cell Genesys and Tocagen. Dr. Twitty has a PhD Molecular Microbiology and Immunology from Oregon Health Sciences University and completed his post-doctoral training with Dr. Bernard Fox at the Earle A. Chiles Research Institute. He is a co-author of 19 publications and a named inventor on three patents.

"Skye Bioscience is leveraging synthetic cannabinoids to potentially achieve safe and effective pharmaceutical compounds to treat ocular diseases. I look forward to building on our mechanistic understanding of this important biological system and enhancing our clinical studies by developing complementary biomarker programs," said Dr. Twitty. "Additionally, I am excited to work with our internal team and strong collaborators to rapidly advance novel therapeutic candidates to further build out Sky Bioscience's pipeline."

"Chris has played an integral role in defining the vision, goals and plans for multiple R&D programs focused on expanding a clinical pipeline with strong intellectual property. He is an accomplished scientist and executive highly skilled in clinical translational science, which will broaden our understanding of this class of molecules. We welcome him and look forward to his integral contribution to Skye," said Punit Dhillon, CEO and Chair of Skye.

## **About Skye Bioscience**

Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs. The Company's lead program, SBI-100 OE, is focused on developing a treatment for glaucoma, the world's leading cause of irreversible blindness. For more information, please visit: [www.skyebioscience.com](http://www.skyebioscience.com).

## **CONTACT**

Investor Relations

Email: [ir@skyebioscience.com](mailto:ir@skyebioscience.com)

Phone: (858) 410-0266

## **FORWARD LOOKING STATEMENTS**

This letter contains forward-looking statements, including statements regarding our product development, business strategy, the timing of clinical trials, and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.



To view the source version of this press release, please visit  
<https://www.newsfilecorp.com/release/147814>

SOURCE Skye Bioscience, Inc.